Ehlers-Danlos Syndrome: Collagen Disorders and Connective Tissue
Manifestations
Ehlers-Danlos syndrome (EDS) represents a spectrum of heritable connective tissue disorders
arising from defects in collagen synthesis, structure, or processing. Over 13 subtypes have
been delineated based on distinct genetic variants impacting collagen assembly and
qualitative or quantitative production. Clinical criteria encompass joint hypermobility, skin
hyperextensibility, tissue fragility, and variable internal organ involvement dependent upon
deficits in specific collagen types. Associations with pain, easy bruising, dislocations,
abnormal wound healing, and vascular/visceral manifestations impact quality of life.
As understanding expands through next-generation sequencing, EDS therapies aim to address
comorbidities through targeted exercise, bracing, surgeries empowering mobility and
vocational participation. Palliative strategies focus managing chronic pain syndromes as a
key priority. Differential diagnoses also include overlapping conditions sharing clinical and
genetic heterogeneity complicated classification. This review summarizes EDS subtypes,
molecular etiologies disrupting collagen genes, multisystem manifestations, diagnostic
criteria, and management strategies promoting wellness through precision care frameworks.
Collagen Overview and Biosynthesis
Collagens represent a family of fibrous structural proteins and ECM components essential to
tissue integrity. 28 types assemble into copolymers and higher-order structures conferring
strength and flexibility:
- Fibrillar collagens (I, II, III) form fibrils providing tensile strength in skin, bone, vessels.
- FACIT collagens (IX, XII, XIV) associate fibrils to other ECM components or cells.
- Transmembrane collagens (XVII, XXIII, XXV) mediate cell-matrix adhesion.
- Multiplexed triple helical domains form after intracellular post-translational hydroxylation,
glycosylation, and extracellular processing steps requiring chaperones, modifying enzymes,
and metals.
Qualitative or quantitative collagen defects disrupt tissue development, repair, and
homeostasis underlying heritable connective tissue disorders.
EDS Subtypes and Genetic Etiologies
13 subtypes delineated based on inheritance patterns and defects in specific collagen
genes/processing enzymes:
- Classical EDS (I, II) - Haploinsufficiency of COL5A1/2 collagen genes.
- Hypermobile EDS - Unknown etiology, associations with tenascin-X, COL3A1 variants.
- Vascular EDS (IV) - Heterozygous COL3A1 mutations cause vascular fragility.
- Kyphoscoliotic (VI) - Recessive proα1(I) collagen (COL1A1, COL1A2) defects cause bone
fragility.
- Arthrochalasia (VIIA, VIIB) - Recessive ADAMTS2/17 mutations impair collagen
processing.
Less common subtypes involve collagen XII, XI, XXII genes or chaperone/enzyme
deficiencies impacting specific collagen assembly steps underlying distinct connective tissue
presentations.
Clinical Features of EDS
Manifestations vary between/within subtypes depending on affected collagen, but may
include:
- Joint hypermobility - Loose/stretchy joints, frequent dislocations, instability.
- Skin hyperextensibility - Stretch marks, smooth/velvety skin, visible veins, easy bruising.
- Tissue fragility - Delayed wound healing, hernias, organ ruptures from minor trauma.
- Musculoskeletal - Scoliosis, pectus deformities, joint pain/subluxations/arthritis.
- Vascular fragility - Spontaneous arterial/intestinal perforations, aortic root dilations.
- Other - Mitral valve prolapse, pudgy fingers, colonic inertia, chronic fatigue,
musculoskeletal pain.
Manifestations vary age-dependently and combined clinical/molecular analysis optimizes
diagnosis.
Diagnosis
Diagnosis requires thorough clinical examination and patient/family histories to evaluate
patterns:
- 2017 International EDS Criteria delineate major/minor features to diagnose major subtypes.
- Genetic counseling assesses mode of inheritance and recurrence risks.
- Molecular testing confirms diagnosis if a pathogenic variant is identified in a tested EDS
gene.
- Differential diagnosis excludes conditions mimicking EDS like Marfan/Loeys-Dietz
syndromes.
Diagnosis guides prognosis, screening/management recommendations, and genetic
counseling of relatives regarding inheritance and reproductive risks where applicable.
Management
Treatment follows a multidisciplinary approach focusing overall wellness:
- Physical/occupational therapy addressing muscle weakness/contractures through
customized exercises.
- Bracing/orthotics minimize joint instability. Splinting assists tissue repair.
- Surgical interventions reconstruct joints, hernias, address vascular/dural ectasia.
- Physician-supervised high-protein diet boosts collagen synthesis.
- Contraceptives used for menorrhagia alleviate bleeding in some subtypes.
- Co-management of chronic pain syndromes utilizes medications, injections, devices.
- Counseling addresses issues like fatigue, anxiety, body image concerns.
- Genetic screening determines risk/carrier status of family members enabling early
interventions optimizing function over the lifespan.
Future prospects
Progress promotes wellness through precision frameworks tailoring integrative care
according to collaborative subtype definitions optimizing outcomes. Identifying modifier
genes impacting variable expressivity and developing anti-fibrotic therapeutics addressing
underlying defects holds promise improving quality of life for individuals affected by
heritable collagen-related connective tissue disorders.
Ehlers-Danlos syndrome (EDS) represents a spectrum of heritable connective tissue disorders
arising from defects in collagen synthesis, structure, or processing. Over 13 subtypes have
been delineated based on distinct genetic variants impacting collagen assembly and
qualitative or quantitative production. Clinical criteria encompass joint hypermobility, skin
hyperextensibility, tissue fragility, and variable internal organ involvement dependent upon
deficits in specific collagen types. Associations with pain, easy bruising, dislocations,
abnormal wound healing, and vascular/visceral manifestations impact quality of life.
As understanding expands through next-generation sequencing, EDS therapies aim to address
comorbidities through targeted exercise, bracing, surgeries empowering mobility and
vocational participation. Palliative strategies focus managing chronic pain syndromes as a
key priority. Differential diagnoses also include overlapping conditions sharing clinical and
genetic heterogeneity complicated classification. This review summarizes EDS subtypes,
molecular etiologies disrupting collagen genes, multisystem manifestations, diagnostic
criteria, and management strategies promoting wellness through precision care frameworks.
Collagen Overview and Biosynthesis
Collagens represent a family of fibrous structural proteins and ECM components essential to
tissue integrity. 28 types assemble into copolymers and higher-order structures conferring
strength and flexibility:
- Fibrillar collagens (I, II, III) form fibrils providing tensile strength in skin, bone, vessels.
- FACIT collagens (IX, XII, XIV) associate fibrils to other ECM components or cells.
- Transmembrane collagens (XVII, XXIII, XXV) mediate cell-matrix adhesion.
- Multiplexed triple helical domains form after intracellular post-translational hydroxylation,
glycosylation, and extracellular processing steps requiring chaperones, modifying enzymes,
and metals.
Qualitative or quantitative collagen defects disrupt tissue development, repair, and
homeostasis underlying heritable connective tissue disorders.
EDS Subtypes and Genetic Etiologies
13 subtypes delineated based on inheritance patterns and defects in specific collagen
genes/processing enzymes:
- Classical EDS (I, II) - Haploinsufficiency of COL5A1/2 collagen genes.
- Hypermobile EDS - Unknown etiology, associations with tenascin-X, COL3A1 variants.
- Vascular EDS (IV) - Heterozygous COL3A1 mutations cause vascular fragility.
- Kyphoscoliotic (VI) - Recessive proα1(I) collagen (COL1A1, COL1A2) defects cause bone
fragility.
- Arthrochalasia (VIIA, VIIB) - Recessive ADAMTS2/17 mutations impair collagen
processing.
Less common subtypes involve collagen XII, XI, XXII genes or chaperone/enzyme
deficiencies impacting specific collagen assembly steps underlying distinct connective tissue
presentations.
Clinical Features of EDS
Manifestations vary between/within subtypes depending on affected collagen, but may
include:
- Joint hypermobility - Loose/stretchy joints, frequent dislocations, instability.
- Skin hyperextensibility - Stretch marks, smooth/velvety skin, visible veins, easy bruising.
- Tissue fragility - Delayed wound healing, hernias, organ ruptures from minor trauma.
- Musculoskeletal - Scoliosis, pectus deformities, joint pain/subluxations/arthritis.
- Vascular fragility - Spontaneous arterial/intestinal perforations, aortic root dilations.
- Other - Mitral valve prolapse, pudgy fingers, colonic inertia, chronic fatigue,
musculoskeletal pain.
Manifestations vary age-dependently and combined clinical/molecular analysis optimizes
diagnosis.
Diagnosis
Diagnosis requires thorough clinical examination and patient/family histories to evaluate
patterns:
- 2017 International EDS Criteria delineate major/minor features to diagnose major subtypes.
- Genetic counseling assesses mode of inheritance and recurrence risks.
- Molecular testing confirms diagnosis if a pathogenic variant is identified in a tested EDS
gene.
- Differential diagnosis excludes conditions mimicking EDS like Marfan/Loeys-Dietz
syndromes.
Diagnosis guides prognosis, screening/management recommendations, and genetic
counseling of relatives regarding inheritance and reproductive risks where applicable.
Management
Treatment follows a multidisciplinary approach focusing overall wellness:
- Physical/occupational therapy addressing muscle weakness/contractures through
customized exercises.
- Bracing/orthotics minimize joint instability. Splinting assists tissue repair.
- Surgical interventions reconstruct joints, hernias, address vascular/dural ectasia.
- Physician-supervised high-protein diet boosts collagen synthesis.
- Contraceptives used for menorrhagia alleviate bleeding in some subtypes.
- Co-management of chronic pain syndromes utilizes medications, injections, devices.
- Counseling addresses issues like fatigue, anxiety, body image concerns.
- Genetic screening determines risk/carrier status of family members enabling early
interventions optimizing function over the lifespan.
Future prospects
Progress promotes wellness through precision frameworks tailoring integrative care
according to collaborative subtype definitions optimizing outcomes. Identifying modifier
genes impacting variable expressivity and developing anti-fibrotic therapeutics addressing
underlying defects holds promise improving quality of life for individuals affected by
heritable collagen-related connective tissue disorders.
Ehlers-Danlos syndrome (EDS) represents a spectrum of heritable connective tissue disorders
arising from defects in collagen synthesis, structure, or processing. Over 13 subtypes have
been delineated based on distinct genetic variants impacting collagen assembly and
qualitative or quantitative production. Clinical criteria encompass joint hypermobility, skin
hyperextensibility, tissue fragility, and variable internal organ involvement dependent upon
deficits in specific collagen types. Associations with pain, easy bruising, dislocations,
abnormal wound healing, and vascular/visceral manifestations impact quality of life.
As understanding expands through next-generation sequencing, EDS therapies aim to address
comorbidities through targeted exercise, bracing, surgeries empowering mobility and
vocational participation. Palliative strategies focus managing chronic pain syndromes as a
key priority. Differential diagnoses also include overlapping conditions sharing clinical and
genetic heterogeneity complicated classification. This review summarizes EDS subtypes,
molecular etiologies disrupting collagen genes, multisystem manifestations, diagnostic
criteria, and management strategies promoting wellness through precision care frameworks.
Collagen Overview and Biosynthesis
Collagens represent a family of fibrous structural proteins and ECM components essential to
tissue integrity. 28 types assemble into copolymers and higher-order structures conferring
strength and flexibility:
- Fibrillar collagens (I, II, III) form fibrils providing tensile strength in skin, bone, vessels.
- FACIT collagens (IX, XII, XIV) associate fibrils to other ECM components or cells.
- Transmembrane collagens (XVII, XXIII, XXV) mediate cell-matrix adhesion.
- Multiplexed triple helical domains form after intracellular post-translational hydroxylation,
glycosylation, and extracellular processing steps requiring chaperones, modifying enzymes,
and metals.
Qualitative or quantitative collagen defects disrupt tissue development, repair, and
homeostasis underlying heritable connective tissue disorders.
EDS Subtypes and Genetic Etiologies
13 subtypes delineated based on inheritance patterns and defects in specific collagen
genes/processing enzymes:
- Classical EDS (I, II) - Haploinsufficiency of COL5A1/2 collagen genes.
- Hypermobile EDS - Unknown etiology, associations with tenascin-X, COL3A1 variants.
- Vascular EDS (IV) - Heterozygous COL3A1 mutations cause vascular fragility.
- Kyphoscoliotic (VI) - Recessive proα1(I) collagen (COL1A1, COL1A2) defects cause bone
fragility.
- Arthrochalasia (VIIA, VIIB) - Recessive ADAMTS2/17 mutations impair collagen
processing.
Less common subtypes involve collagen XII, XI, XXII genes or chaperone/enzyme
deficiencies impacting specific collagen assembly steps underlying distinct connective tissue
presentations.
Clinical Features of EDS
Manifestations vary between/within subtypes depending on affected collagen, but may
include:
- Joint hypermobility - Loose/stretchy joints, frequent dislocations, instability.
- Skin hyperextensibility - Stretch marks, smooth/velvety skin, visible veins, easy bruising.
- Tissue fragility - Delayed wound healing, hernias, organ ruptures from minor trauma.
- Musculoskeletal - Scoliosis, pectus deformities, joint pain/subluxations/arthritis.
- Vascular fragility - Spontaneous arterial/intestinal perforations, aortic root dilations.
- Other - Mitral valve prolapse, pudgy fingers, colonic inertia, chronic fatigue,
musculoskeletal pain.
Manifestations vary age-dependently and combined clinical/molecular analysis optimizes
diagnosis.
Diagnosis
Diagnosis requires thorough clinical examination and patient/family histories to evaluate
patterns:
- 2017 International EDS Criteria delineate major/minor features to diagnose major subtypes.
- Genetic counseling assesses mode of inheritance and recurrence risks.
- Molecular testing confirms diagnosis if a pathogenic variant is identified in a tested EDS
gene.
- Differential diagnosis excludes conditions mimicking EDS like Marfan/Loeys-Dietz
syndromes.
Diagnosis guides prognosis, screening/management recommendations, and genetic
counseling of relatives regarding inheritance and reproductive risks where applicable.
Management
Treatment follows a multidisciplinary approach focusing overall wellness:
- Physical/occupational therapy addressing muscle weakness/contractures through
customized exercises.
- Bracing/orthotics minimize joint instability. Splinting assists tissue repair.
- Surgical interventions reconstruct joints, hernias, address vascular/dural ectasia.
- Physician-supervised high-protein diet boosts collagen synthesis.
- Contraceptives used for menorrhagia alleviate bleeding in some subtypes.
- Co-management of chronic pain syndromes utilizes medications, injections, devices.
- Counseling addresses issues like fatigue, anxiety, body image concerns.
- Genetic screening determines risk/carrier status of family members enabling early
interventions optimizing function over the lifespan.
Future prospects
Progress promotes wellness through precision frameworks tailoring integrative care
according to collaborative subtype definitions optimizing outcomes. Identifying modifier
genes impacting variable expressivity and developing anti-fibrotic therapeutics addressing
underlying defects holds promise improving quality of life for individuals affected by
heritable collagen-related connective tissue disorders.
Ehlers-Danlos syndrome (EDS) represents a spectrum of heritable connective tissue disorders
arising from defects in collagen synthesis, structure, or processing. Over 13 subtypes have
been delineated based on distinct genetic variants impacting collagen assembly and
qualitative or quantitative production. Clinical criteria encompass joint hypermobility, skin
hyperextensibility, tissue fragility, and variable internal organ involvement dependent upon
deficits in specific collagen types. Associations with pain, easy bruising, dislocations,
abnormal wound healing, and vascular/visceral manifestations impact quality of life.
As understanding expands through next-generation sequencing, EDS therapies aim to address
comorbidities through targeted exercise, bracing, surgeries empowering mobility and
vocational participation. Palliative strategies focus managing chronic pain syndromes as a
key priority. Differential diagnoses also include overlapping conditions sharing clinical and
genetic heterogeneity complicated classification. This review summarizes EDS subtypes,
molecular etiologies disrupting collagen genes, multisystem manifestations, diagnostic
criteria, and management strategies promoting wellness through precision care frameworks.
Collagen Overview and Biosynthesis
Collagens represent a family of fibrous structural proteins and ECM components essential to
tissue integrity. 28 types assemble into copolymers and higher-order structures conferring
strength and flexibility:
- Fibrillar collagens (I, II, III) form fibrils providing tensile strength in skin, bone, vessels.
- FACIT collagens (IX, XII, XIV) associate fibrils to other ECM components or cells.
- Transmembrane collagens (XVII, XXIII, XXV) mediate cell-matrix adhesion.
- Multiplexed triple helical domains form after intracellular post-translational hydroxylation,
glycosylation, and extracellular processing steps requiring chaperones, modifying enzymes,
and metals.
Qualitative or quantitative collagen defects disrupt tissue development, repair, and
homeostasis underlying heritable connective tissue disorders.
EDS Subtypes and Genetic Etiologies
13 subtypes delineated based on inheritance patterns and defects in specific collagen
genes/processing enzymes:
- Classical EDS (I, II) - Haploinsufficiency of COL5A1/2 collagen genes.
- Hypermobile EDS - Unknown etiology, associations with tenascin-X, COL3A1 variants.
- Vascular EDS (IV) - Heterozygous COL3A1 mutations cause vascular fragility.
- Kyphoscoliotic (VI) - Recessive proα1(I) collagen (COL1A1, COL1A2) defects cause bone
fragility.
- Arthrochalasia (VIIA, VIIB) - Recessive ADAMTS2/17 mutations impair collagen
processing.
Less common subtypes involve collagen XII, XI, XXII genes or chaperone/enzyme
deficiencies impacting specific collagen assembly steps underlying distinct connective tissue
presentations.
Clinical Features of EDS
Manifestations vary between/within subtypes depending on affected collagen, but may
include:
- Joint hypermobility - Loose/stretchy joints, frequent dislocations, instability.
- Skin hyperextensibility - Stretch marks, smooth/velvety skin, visible veins, easy bruising.
- Tissue fragility - Delayed wound healing, hernias, organ ruptures from minor trauma.
- Musculoskeletal - Scoliosis, pectus deformities, joint pain/subluxations/arthritis.
- Vascular fragility - Spontaneous arterial/intestinal perforations, aortic root dilations.
- Other - Mitral valve prolapse, pudgy fingers, colonic inertia, chronic fatigue,
musculoskeletal pain.
Manifestations vary age-dependently and combined clinical/molecular analysis optimizes
diagnosis.
Diagnosis
Diagnosis requires thorough clinical examination and patient/family histories to evaluate
patterns:
- 2017 International EDS Criteria delineate major/minor features to diagnose major subtypes.
- Genetic counseling assesses mode of inheritance and recurrence risks.
- Molecular testing confirms diagnosis if a pathogenic variant is identified in a tested EDS
gene.
- Differential diagnosis excludes conditions mimicking EDS like Marfan/Loeys-Dietz
syndromes.
Diagnosis guides prognosis, screening/management recommendations, and genetic
counseling of relatives regarding inheritance and reproductive risks where applicable.
Management
Treatment follows a multidisciplinary approach focusing overall wellness:
- Physical/occupational therapy addressing muscle weakness/contractures through
customized exercises.
- Bracing/orthotics minimize joint instability. Splinting assists tissue repair.
- Surgical interventions reconstruct joints, hernias, address vascular/dural ectasia.
- Physician-supervised high-protein diet boosts collagen synthesis.
- Contraceptives used for menorrhagia alleviate bleeding in some subtypes.
- Co-management of chronic pain syndromes utilizes medications, injections, devices.
- Counseling addresses issues like fatigue, anxiety, body image concerns.
- Genetic screening determines risk/carrier status of family members enabling early
interventions optimizing function over the lifespan.
Future prospects
Progress promotes wellness through precision frameworks tailoring integrative care
according to collaborative subtype definitions optimizing outcomes. Identifying modifier
genes impacting variable expressivity and developing anti-fibrotic therapeutics addressing
underlying defects holds promise improving quality of life for individuals affected by
heritable collagen-related connective tissue disorders.
Ehlers-Danlos syndrome (EDS) represents a spectrum of heritable connective tissue disorders
arising from defects in collagen synthesis, structure, or processing. Over 13 subtypes have
been delineated based on distinct genetic variants impacting collagen assembly and
qualitative or quantitative production. Clinical criteria encompass joint hypermobility, skin
hyperextensibility, tissue fragility, and variable internal organ involvement dependent upon
deficits in specific collagen types. Associations with pain, easy bruising, dislocations,
abnormal wound healing, and vascular/visceral manifestations impact quality of life.
As understanding expands through next-generation sequencing, EDS therapies aim to address
comorbidities through targeted exercise, bracing, surgeries empowering mobility and
vocational participation. Palliative strategies focus managing chronic pain syndromes as a
key priority. Differential diagnoses also include overlapping conditions sharing clinical and
genetic heterogeneity complicated classification. This review summarizes EDS subtypes,
molecular etiologies disrupting collagen genes, multisystem manifestations, diagnostic
criteria, and management strategies promoting wellness through precision care frameworks.
Collagen Overview and Biosynthesis
Collagens represent a family of fibrous structural proteins and ECM components essential to
tissue integrity. 28 types assemble into copolymers and higher-order structures conferring
strength and flexibility:
- Fibrillar collagens (I, II, III) form fibrils providing tensile strength in skin, bone, vessels.
- FACIT collagens (IX, XII, XIV) associate fibrils to other ECM components or cells.
- Transmembrane collagens (XVII, XXIII, XXV) mediate cell-matrix adhesion.
- Multiplexed triple helical domains form after intracellular post-translational hydroxylation,
glycosylation, and extracellular processing steps requiring chaperones, modifying enzymes,
and metals.
Qualitative or quantitative collagen defects disrupt tissue development, repair, and
homeostasis underlying heritable connective tissue disorders.
EDS Subtypes and Genetic Etiologies
13 subtypes delineated based on inheritance patterns and defects in specific collagen
genes/processing enzymes:
- Classical EDS (I, II) - Haploinsufficiency of COL5A1/2 collagen genes.
- Hypermobile EDS - Unknown etiology, associations with tenascin-X, COL3A1 variants.
- Vascular EDS (IV) - Heterozygous COL3A1 mutations cause vascular fragility.
- Kyphoscoliotic (VI) - Recessive proα1(I) collagen (COL1A1, COL1A2) defects cause bone
fragility.
- Arthrochalasia (VIIA, VIIB) - Recessive ADAMTS2/17 mutations impair collagen
processing.
Less common subtypes involve collagen XII, XI, XXII genes or chaperone/enzyme
deficiencies impacting specific collagen assembly steps underlying distinct connective tissue
presentations.
Clinical Features of EDS
Manifestations vary between/within subtypes depending on affected collagen, but may
include:
- Joint hypermobility - Loose/stretchy joints, frequent dislocations, instability.
- Skin hyperextensibility - Stretch marks, smooth/velvety skin, visible veins, easy bruising.
- Tissue fragility - Delayed wound healing, hernias, organ ruptures from minor trauma.
- Musculoskeletal - Scoliosis, pectus deformities, joint pain/subluxations/arthritis.
- Vascular fragility - Spontaneous arterial/intestinal perforations, aortic root dilations.
- Other - Mitral valve prolapse, pudgy fingers, colonic inertia, chronic fatigue,
musculoskeletal pain.
Manifestations vary age-dependently and combined clinical/molecular analysis optimizes
diagnosis.
Diagnosis
Diagnosis requires thorough clinical examination and patient/family histories to evaluate
patterns:
- 2017 International EDS Criteria delineate major/minor features to diagnose major subtypes.
- Genetic counseling assesses mode of inheritance and recurrence risks.
- Molecular testing confirms diagnosis if a pathogenic variant is identified in a tested EDS
gene.
- Differential diagnosis excludes conditions mimicking EDS like Marfan/Loeys-Dietz
syndromes.
Diagnosis guides prognosis, screening/management recommendations, and genetic
counseling of relatives regarding inheritance and reproductive risks where applicable.
Management
Treatment follows a multidisciplinary approach focusing overall wellness:
- Physical/occupational therapy addressing muscle weakness/contractures through
customized exercises.
- Bracing/orthotics minimize joint instability. Splinting assists tissue repair.
- Surgical interventions reconstruct joints, hernias, address vascular/dural ectasia.
- Physician-supervised high-protein diet boosts collagen synthesis.
- Contraceptives used for menorrhagia alleviate bleeding in some subtypes.
- Co-management of chronic pain syndromes utilizes medications, injections, devices.
- Counseling addresses issues like fatigue, anxiety, body image concerns.
- Genetic screening determines risk/carrier status of family members enabling early
interventions optimizing function over the lifespan.
Future prospects
Progress promotes wellness through precision frameworks tailoring integrative care
according to collaborative subtype definitions optimizing outcomes. Identifying modifier
genes impacting variable expressivity and developing anti-fibrotic therapeutics addressing
underlying defects holds promise improving quality of life for individuals affected by
heritable collagen-related connective tissue disorders.
Ehlers-Danlos syndrome (EDS) represents a spectrum of heritable connective tissue disorders
arising from defects in collagen synthesis, structure, or processing. Over 13 subtypes have
been delineated based on distinct genetic variants impacting collagen assembly and
qualitative or quantitative production. Clinical criteria encompass joint hypermobility, skin
hyperextensibility, tissue fragility, and variable internal organ involvement dependent upon
deficits in specific collagen types. Associations with pain, easy bruising, dislocations,
abnormal wound healing, and vascular/visceral manifestations impact quality of life.
As understanding expands through next-generation sequencing, EDS therapies aim to address
comorbidities through targeted exercise, bracing, surgeries empowering mobility and
vocational participation. Palliative strategies focus managing chronic pain syndromes as a
key priority. Differential diagnoses also include overlapping conditions sharing clinical and
genetic heterogeneity complicated classification. This review summarizes EDS subtypes,
molecular etiologies disrupting collagen genes, multisystem manifestations, diagnostic
criteria, and management strategies promoting wellness through precision care frameworks.
Collagen Overview and Biosynthesis
Collagens represent a family of fibrous structural proteins and ECM components essential to
tissue integrity. 28 types assemble into copolymers and higher-order structures conferring
strength and flexibility:
- Fibrillar collagens (I, II, III) form fibrils providing tensile strength in skin, bone, vessels.
- FACIT collagens (IX, XII, XIV) associate fibrils to other ECM components or cells.
- Transmembrane collagens (XVII, XXIII, XXV) mediate cell-matrix adhesion.
- Multiplexed triple helical domains form after intracellular post-translational hydroxylation,
glycosylation, and extracellular processing steps requiring chaperones, modifying enzymes,
and metals.
Qualitative or quantitative collagen defects disrupt tissue development, repair, and
homeostasis underlying heritable connective tissue disorders.
EDS Subtypes and Genetic Etiologies
13 subtypes delineated based on inheritance patterns and defects in specific collagen
genes/processing enzymes:
- Classical EDS (I, II) - Haploinsufficiency of COL5A1/2 collagen genes.
- Hypermobile EDS - Unknown etiology, associations with tenascin-X, COL3A1 variants.
- Vascular EDS (IV) - Heterozygous COL3A1 mutations cause vascular fragility.
- Kyphoscoliotic (VI) - Recessive proα1(I) collagen (COL1A1, COL1A2) defects cause bone
fragility.
- Arthrochalasia (VIIA, VIIB) - Recessive ADAMTS2/17 mutations impair collagen
processing.
Less common subtypes involve collagen XII, XI, XXII genes or chaperone/enzyme
deficiencies impacting specific collagen assembly steps underlying distinct connective tissue
presentations.
Clinical Features of EDS
Manifestations vary between/within subtypes depending on affected collagen, but may
include:
- Joint hypermobility - Loose/stretchy joints, frequent dislocations, instability.
- Skin hyperextensibility - Stretch marks, smooth/velvety skin, visible veins, easy bruising.
- Tissue fragility - Delayed wound healing, hernias, organ ruptures from minor trauma.
- Musculoskeletal - Scoliosis, pectus deformities, joint pain/subluxations/arthritis.
- Vascular fragility - Spontaneous arterial/intestinal perforations, aortic root dilations.
- Other - Mitral valve prolapse, pudgy fingers, colonic inertia, chronic fatigue,
musculoskeletal pain.
Manifestations vary age-dependently and combined clinical/molecular analysis optimizes
diagnosis.
Diagnosis
Diagnosis requires thorough clinical examination and patient/family histories to evaluate
patterns:
- 2017 International EDS Criteria delineate major/minor features to diagnose major subtypes.
- Genetic counseling assesses mode of inheritance and recurrence risks.
- Molecular testing confirms diagnosis if a pathogenic variant is identified in a tested EDS
gene.
- Differential diagnosis excludes conditions mimicking EDS like Marfan/Loeys-Dietz
syndromes.
Diagnosis guides prognosis, screening/management recommendations, and genetic
counseling of relatives regarding inheritance and reproductive risks where applicable.
Management
Treatment follows a multidisciplinary approach focusing overall wellness:
- Physical/occupational therapy addressing muscle weakness/contractures through
customized exercises.
- Bracing/orthotics minimize joint instability. Splinting assists tissue repair.
- Surgical interventions reconstruct joints, hernias, address vascular/dural ectasia.
- Physician-supervised high-protein diet boosts collagen synthesis.
- Contraceptives used for menorrhagia alleviate bleeding in some subtypes.
- Co-management of chronic pain syndromes utilizes medications, injections, devices.
- Counseling addresses issues like fatigue, anxiety, body image concerns.
- Genetic screening determines risk/carrier status of family members enabling early
interventions optimizing function over the lifespan.
Future prospects
Progress promotes wellness through precision frameworks tailoring integrative care
according to collaborative subtype definitions optimizing outcomes. Identifying modifier
genes impacting variable expressivity and developing anti-fibrotic therapeutics addressing
underlying defects holds promise improving quality of life for individuals affected by
heritable collagen-related connective tissue disorders.
Ehlers-Danlos syndrome (EDS) represents a spectrum of heritable connective tissue disorders
arising from defects in collagen synthesis, structure, or processing. Over 13 subtypes have
been delineated based on distinct genetic variants impacting collagen assembly and
qualitative or quantitative production. Clinical criteria encompass joint hypermobility, skin
hyperextensibility, tissue fragility, and variable internal organ involvement dependent upon
deficits in specific collagen types. Associations with pain, easy bruising, dislocations,
abnormal wound healing, and vascular/visceral manifestations impact quality of life.
As understanding expands through next-generation sequencing, EDS therapies aim to address
comorbidities through targeted exercise, bracing, surgeries empowering mobility and
vocational participation. Palliative strategies focus managing chronic pain syndromes as a
key priority. Differential diagnoses also include overlapping conditions sharing clinical and
genetic heterogeneity complicated classification. This review summarizes EDS subtypes,
molecular etiologies disrupting collagen genes, multisystem manifestations, diagnostic
criteria, and management strategies promoting wellness through precision care frameworks.
Collagen Overview and Biosynthesis
Collagens represent a family of fibrous structural proteins and ECM components essential to
tissue integrity. 28 types assemble into copolymers and higher-order structures conferring
strength and flexibility:
- Fibrillar collagens (I, II, III) form fibrils providing tensile strength in skin, bone, vessels.
- FACIT collagens (IX, XII, XIV) associate fibrils to other ECM components or cells.
- Transmembrane collagens (XVII, XXIII, XXV) mediate cell-matrix adhesion.
- Multiplexed triple helical domains form after intracellular post-translational hydroxylation,
glycosylation, and extracellular processing steps requiring chaperones, modifying enzymes,
and metals.
Qualitative or quantitative collagen defects disrupt tissue development, repair, and
homeostasis underlying heritable connective tissue disorders.
EDS Subtypes and Genetic Etiologies
13 subtypes delineated based on inheritance patterns and defects in specific collagen
genes/processing enzymes:
- Classical EDS (I, II) - Haploinsufficiency of COL5A1/2 collagen genes.
- Hypermobile EDS - Unknown etiology, associations with tenascin-X, COL3A1 variants.
- Vascular EDS (IV) - Heterozygous COL3A1 mutations cause vascular fragility.
- Kyphoscoliotic (VI) - Recessive proα1(I) collagen (COL1A1, COL1A2) defects cause bone
fragility.
- Arthrochalasia (VIIA, VIIB) - Recessive ADAMTS2/17 mutations impair collagen
processing.
Less common subtypes involve collagen XII, XI, XXII genes or chaperone/enzyme
deficiencies impacting specific collagen assembly steps underlying distinct connective tissue
presentations.
Clinical Features of EDS
Manifestations vary between/within subtypes depending on affected collagen, but may
include:
- Joint hypermobility - Loose/stretchy joints, frequent dislocations, instability.
- Skin hyperextensibility - Stretch marks, smooth/velvety skin, visible veins, easy bruising.
- Tissue fragility - Delayed wound healing, hernias, organ ruptures from minor trauma.
- Musculoskeletal - Scoliosis, pectus deformities, joint pain/subluxations/arthritis.
- Vascular fragility - Spontaneous arterial/intestinal perforations, aortic root dilations.
- Other - Mitral valve prolapse, pudgy fingers, colonic inertia, chronic fatigue,
musculoskeletal pain.
Manifestations vary age-dependently and combined clinical/molecular analysis optimizes
diagnosis.
Diagnosis
Diagnosis requires thorough clinical examination and patient/family histories to evaluate
patterns:
- 2017 International EDS Criteria delineate major/minor features to diagnose major subtypes.
- Genetic counseling assesses mode of inheritance and recurrence risks.
- Molecular testing confirms diagnosis if a pathogenic variant is identified in a tested EDS
gene.
- Differential diagnosis excludes conditions mimicking EDS like Marfan/Loeys-Dietz
syndromes.
Diagnosis guides prognosis, screening/management recommendations, and genetic
counseling of relatives regarding inheritance and reproductive risks where applicable.
Management
Treatment follows a multidisciplinary approach focusing overall wellness:
- Physical/occupational therapy addressing muscle weakness/contractures through
customized exercises.
- Bracing/orthotics minimize joint instability. Splinting assists tissue repair.
- Surgical interventions reconstruct joints, hernias, address vascular/dural ectasia.
- Physician-supervised high-protein diet boosts collagen synthesis.
- Contraceptives used for menorrhagia alleviate bleeding in some subtypes.
- Co-management of chronic pain syndromes utilizes medications, injections, devices.
- Counseling addresses issues like fatigue, anxiety, body image concerns.
- Genetic screening determines risk/carrier status of family members enabling early
interventions optimizing function over the lifespan.
Future prospects
Progress promotes wellness through precision frameworks tailoring integrative care
according to collaborative subtype definitions optimizing outcomes. Identifying modifier
genes impacting variable expressivity and developing anti-fibrotic therapeutics addressing
underlying defects holds promise improving quality of life for individuals affected by
heritable collagen-related connective tissue disorders.
Ehlers-Danlos syndrome (EDS) represents a spectrum of heritable connective tissue disorders
arising from defects in collagen synthesis, structure, or processing. Over 13 subtypes have
been delineated based on distinct genetic variants impacting collagen assembly and
qualitative or quantitative production. Clinical criteria encompass joint hypermobility, skin
hyperextensibility, tissue fragility, and variable internal organ involvement dependent upon
deficits in specific collagen types. Associations with pain, easy bruising, dislocations,
abnormal wound healing, and vascular/visceral manifestations impact quality of life.
As understanding expands through next-generation sequencing, EDS therapies aim to address
comorbidities through targeted exercise, bracing, surgeries empowering mobility and
vocational participation. Palliative strategies focus managing chronic pain syndromes as a
key priority. Differential diagnoses also include overlapping conditions sharing clinical and
genetic heterogeneity complicated classification. This review summarizes EDS subtypes,
molecular etiologies disrupting collagen genes, multisystem manifestations, diagnostic
criteria, and management strategies promoting wellness through precision care frameworks.
Collagen Overview and Biosynthesis
Collagens represent a family of fibrous structural proteins and ECM components essential to
tissue integrity. 28 types assemble into copolymers and higher-order structures conferring
strength and flexibility:
- Fibrillar collagens (I, II, III) form fibrils providing tensile strength in skin, bone, vessels.
- FACIT collagens (IX, XII, XIV) associate fibrils to other ECM components or cells.
- Transmembrane collagens (XVII, XXIII, XXV) mediate cell-matrix adhesion.
- Multiplexed triple helical domains form after intracellular post-translational hydroxylation,
glycosylation, and extracellular processing steps requiring chaperones, modifying enzymes,
and metals.
Qualitative or quantitative collagen defects disrupt tissue development, repair, and
homeostasis underlying heritable connective tissue disorders.
EDS Subtypes and Genetic Etiologies
13 subtypes delineated based on inheritance patterns and defects in specific collagen
genes/processing enzymes:
- Classical EDS (I, II) - Haploinsufficiency of COL5A1/2 collagen genes.
- Hypermobile EDS - Unknown etiology, associations with tenascin-X, COL3A1 variants.
- Vascular EDS (IV) - Heterozygous COL3A1 mutations cause vascular fragility.
- Kyphoscoliotic (VI) - Recessive proα1(I) collagen (COL1A1, COL1A2) defects cause bone
fragility.
- Arthrochalasia (VIIA, VIIB) - Recessive ADAMTS2/17 mutations impair collagen
processing.
Less common subtypes involve collagen XII, XI, XXII genes or chaperone/enzyme
deficiencies impacting specific collagen assembly steps underlying distinct connective tissue
presentations.
Clinical Features of EDS
Manifestations vary between/within subtypes depending on affected collagen, but may
include:
- Joint hypermobility - Loose/stretchy joints, frequent dislocations, instability.
- Skin hyperextensibility - Stretch marks, smooth/velvety skin, visible veins, easy bruising.
- Tissue fragility - Delayed wound healing, hernias, organ ruptures from minor trauma.
- Musculoskeletal - Scoliosis, pectus deformities, joint pain/subluxations/arthritis.
- Vascular fragility - Spontaneous arterial/intestinal perforations, aortic root dilations.
- Other - Mitral valve prolapse, pudgy fingers, colonic inertia, chronic fatigue,
musculoskeletal pain.
Manifestations vary age-dependently and combined clinical/molecular analysis optimizes
diagnosis.
Diagnosis
Diagnosis requires thorough clinical examination and patient/family histories to evaluate
patterns:
- 2017 International EDS Criteria delineate major/minor features to diagnose major subtypes.
- Genetic counseling assesses mode of inheritance and recurrence risks.
- Molecular testing confirms diagnosis if a pathogenic variant is identified in a tested EDS
gene.
- Differential diagnosis excludes conditions mimicking EDS like Marfan/Loeys-Dietz
syndromes.
Diagnosis guides prognosis, screening/management recommendations, and genetic
counseling of relatives regarding inheritance and reproductive risks where applicable.
Management
Treatment follows a multidisciplinary approach focusing overall wellness:
- Physical/occupational therapy addressing muscle weakness/contractures through
customized exercises.
- Bracing/orthotics minimize joint instability. Splinting assists tissue repair.
- Surgical interventions reconstruct joints, hernias, address vascular/dural ectasia.
- Physician-supervised high-protein diet boosts collagen synthesis.
- Contraceptives used for menorrhagia alleviate bleeding in some subtypes.
- Co-management of chronic pain syndromes utilizes medications, injections, devices.
- Counseling addresses issues like fatigue, anxiety, body image concerns.
- Genetic screening determines risk/carrier status of family members enabling early
interventions optimizing function over the lifespan.
Future prospects
Progress promotes wellness through precision frameworks tailoring integrative care
according to collaborative subtype definitions optimizing outcomes. Identifying modifier
genes impacting variable expressivity and developing anti-fibrotic therapeutics addressing
underlying defects holds promise improving quality of life for individuals affected by
heritable collagen-related connective tissue disorders.
Ehlers-Danlos syndrome (EDS) represents a spectrum of heritable connective tissue disorders
arising from defects in collagen synthesis, structure, or processing. Over 13 subtypes have
been delineated based on distinct genetic variants impacting collagen assembly and
qualitative or quantitative production. Clinical criteria encompass joint hypermobility, skin
hyperextensibility, tissue fragility, and variable internal organ involvement dependent upon
deficits in specific collagen types. Associations with pain, easy bruising, dislocations,
abnormal wound healing, and vascular/visceral manifestations impact quality of life.
As understanding expands through next-generation sequencing, EDS therapies aim to address
comorbidities through targeted exercise, bracing, surgeries empowering mobility and
vocational participation. Palliative strategies focus managing chronic pain syndromes as a
key priority. Differential diagnoses also include overlapping conditions sharing clinical and
genetic heterogeneity complicated classification. This review summarizes EDS subtypes,
molecular etiologies disrupting collagen genes, multisystem manifestations, diagnostic
criteria, and management strategies promoting wellness through precision care frameworks.
Collagen Overview and Biosynthesis
Collagens represent a family of fibrous structural proteins and ECM components essential to
tissue integrity. 28 types assemble into copolymers and higher-order structures conferring
strength and flexibility:
- Fibrillar collagens (I, II, III) form fibrils providing tensile strength in skin, bone, vessels.
- FACIT collagens (IX, XII, XIV) associate fibrils to other ECM components or cells.
- Transmembrane collagens (XVII, XXIII, XXV) mediate cell-matrix adhesion.
- Multiplexed triple helical domains form after intracellular post-translational hydroxylation,
glycosylation, and extracellular processing steps requiring chaperones, modifying enzymes,
and metals.
Qualitative or quantitative collagen defects disrupt tissue development, repair, and
homeostasis underlying heritable connective tissue disorders.
EDS Subtypes and Genetic Etiologies
13 subtypes delineated based on inheritance patterns and defects in specific collagen
genes/processing enzymes:
- Classical EDS (I, II) - Haploinsufficiency of COL5A1/2 collagen genes.
- Hypermobile EDS - Unknown etiology, associations with tenascin-X, COL3A1 variants.
- Vascular EDS (IV) - Heterozygous COL3A1 mutations cause vascular fragility.
- Kyphoscoliotic (VI) - Recessive proα1(I) collagen (COL1A1, COL1A2) defects cause bone
fragility.
- Arthrochalasia (VIIA, VIIB) - Recessive ADAMTS2/17 mutations impair collagen
processing.
Less common subtypes involve collagen XII, XI, XXII genes or chaperone/enzyme
deficiencies impacting specific collagen assembly steps underlying distinct connective tissue
presentations.
Clinical Features of EDS
Manifestations vary between/within subtypes depending on affected collagen, but may
include:
- Joint hypermobility - Loose/stretchy joints, frequent dislocations, instability.
- Skin hyperextensibility - Stretch marks, smooth/velvety skin, visible veins, easy bruising.
- Tissue fragility - Delayed wound healing, hernias, organ ruptures from minor trauma.
- Musculoskeletal - Scoliosis, pectus deformities, joint pain/subluxations/arthritis.
- Vascular fragility - Spontaneous arterial/intestinal perforations, aortic root dilations.
- Other - Mitral valve prolapse, pudgy fingers, colonic inertia, chronic fatigue,
musculoskeletal pain.
Manifestations vary age-dependently and combined clinical/molecular analysis optimizes
diagnosis.
Diagnosis
Diagnosis requires thorough clinical examination and patient/family histories to evaluate
patterns:
- 2017 International EDS Criteria delineate major/minor features to diagnose major subtypes.
- Genetic counseling assesses mode of inheritance and recurrence risks.
- Molecular testing confirms diagnosis if a pathogenic variant is identified in a tested EDS
gene.
- Differential diagnosis excludes conditions mimicking EDS like Marfan/Loeys-Dietz
syndromes.
Diagnosis guides prognosis, screening/management recommendations, and genetic
counseling of relatives regarding inheritance and reproductive risks where applicable.
Management
Treatment follows a multidisciplinary approach focusing overall wellness:
- Physical/occupational therapy addressing muscle weakness/contractures through
customized exercises.
- Bracing/orthotics minimize joint instability. Splinting assists tissue repair.
- Surgical interventions reconstruct joints, hernias, address vascular/dural ectasia.
- Physician-supervised high-protein diet boosts collagen synthesis.
- Contraceptives used for menorrhagia alleviate bleeding in some subtypes.
- Co-management of chronic pain syndromes utilizes medications, injections, devices.
- Counseling addresses issues like fatigue, anxiety, body image concerns.
- Genetic screening determines risk/carrier status of family members enabling early
interventions optimizing function over the lifespan.
Future prospects
Progress promotes wellness through precision frameworks tailoring integrative care
according to collaborative subtype definitions optimizing outcomes. Identifying modifier
genes impacting variable expressivity and developing anti-fibrotic therapeutics addressing
underlying defects holds promise improving quality of life for individuals affected by
heritable collagen-related connective tissue disorders.
Ehlers-Danlos syndrome (EDS) represents a spectrum of heritable connective tissue disorders
arising from defects in collagen synthesis, structure, or processing. Over 13 subtypes have
been delineated based on distinct genetic variants impacting collagen assembly and
qualitative or quantitative production. Clinical criteria encompass joint hypermobility, skin
hyperextensibility, tissue fragility, and variable internal organ involvement dependent upon
deficits in specific collagen types. Associations with pain, easy bruising, dislocations,
abnormal wound healing, and vascular/visceral manifestations impact quality of life.
As understanding expands through next-generation sequencing, EDS therapies aim to address
comorbidities through targeted exercise, bracing, surgeries empowering mobility and
vocational participation. Palliative strategies focus managing chronic pain syndromes as a
key priority. Differential diagnoses also include overlapping conditions sharing clinical and
genetic heterogeneity complicated classification. This review summarizes EDS subtypes,
molecular etiologies disrupting collagen genes, multisystem manifestations, diagnostic
criteria, and management strategies promoting wellness through precision care frameworks.
Collagen Overview and Biosynthesis
Collagens represent a family of fibrous structural proteins and ECM components essential to
tissue integrity. 28 types assemble into copolymers and higher-order structures conferring
strength and flexibility:
- Fibrillar collagens (I, II, III) form fibrils providing tensile strength in skin, bone, vessels.
- FACIT collagens (IX, XII, XIV) associate fibrils to other ECM components or cells.
- Transmembrane collagens (XVII, XXIII, XXV) mediate cell-matrix adhesion.
- Multiplexed triple helical domains form after intracellular post-translational hydroxylation,
glycosylation, and extracellular processing steps requiring chaperones, modifying enzymes,
and metals.
Qualitative or quantitative collagen defects disrupt tissue development, repair, and
homeostasis underlying heritable connective tissue disorders.
EDS Subtypes and Genetic Etiologies
13 subtypes delineated based on inheritance patterns and defects in specific collagen
genes/processing enzymes:
- Classical EDS (I, II) - Haploinsufficiency of COL5A1/2 collagen genes.
- Hypermobile EDS - Unknown etiology, associations with tenascin-X, COL3A1 variants.
- Vascular EDS (IV) - Heterozygous COL3A1 mutations cause vascular fragility.
- Kyphoscoliotic (VI) - Recessive proα1(I) collagen (COL1A1, COL1A2) defects cause bone
fragility.
- Arthrochalasia (VIIA, VIIB) - Recessive ADAMTS2/17 mutations impair collagen
processing.
Less common subtypes involve collagen XII, XI, XXII genes or chaperone/enzyme
deficiencies impacting specific collagen assembly steps underlying distinct connective tissue
presentations.
Clinical Features of EDS
Manifestations vary between/within subtypes depending on affected collagen, but may
include:
- Joint hypermobility - Loose/stretchy joints, frequent dislocations, instability.
- Skin hyperextensibility - Stretch marks, smooth/velvety skin, visible veins, easy bruising.
- Tissue fragility - Delayed wound healing, hernias, organ ruptures from minor trauma.
- Musculoskeletal - Scoliosis, pectus deformities, joint pain/subluxations/arthritis.
- Vascular fragility - Spontaneous arterial/intestinal perforations, aortic root dilations.
- Other - Mitral valve prolapse, pudgy fingers, colonic inertia, chronic fatigue,
musculoskeletal pain.
Manifestations vary age-dependently and combined clinical/molecular analysis optimizes
diagnosis.
Diagnosis
Diagnosis requires thorough clinical examination and patient/family histories to evaluate
patterns:
- 2017 International EDS Criteria delineate major/minor features to diagnose major subtypes.
- Genetic counseling assesses mode of inheritance and recurrence risks.
- Molecular testing confirms diagnosis if a pathogenic variant is identified in a tested EDS
gene.
- Differential diagnosis excludes conditions mimicking EDS like Marfan/Loeys-Dietz
syndromes.
Diagnosis guides prognosis, screening/management recommendations, and genetic
counseling of relatives regarding inheritance and reproductive risks where applicable.
Management
Treatment follows a multidisciplinary approach focusing overall wellness:
- Physical/occupational therapy addressing muscle weakness/contractures through
customized exercises.
- Bracing/orthotics minimize joint instability. Splinting assists tissue repair.
- Surgical interventions reconstruct joints, hernias, address vascular/dural ectasia.
- Physician-supervised high-protein diet boosts collagen synthesis.
- Contraceptives used for menorrhagia alleviate bleeding in some subtypes.
- Co-management of chronic pain syndromes utilizes medications, injections, devices.
- Counseling addresses issues like fatigue, anxiety, body image concerns.
- Genetic screening determines risk/carrier status of family members enabling early
interventions optimizing function over the lifespan.
Future prospects
Progress promotes wellness through precision frameworks tailoring integrative care
according to collaborative subtype definitions optimizing outcomes. Identifying modifier
genes impacting variable expressivity and developing anti-fibrotic therapeutics addressing
underlying defects holds promise improving quality of life for individuals affected by
heritable collagen-related connective tissue disorders.
Ehlers-Danlos syndrome (EDS) represents a spectrum of heritable connective tissue disorders
arising from defects in collagen synthesis, structure, or processing. Over 13 subtypes have
been delineated based on distinct genetic variants impacting collagen assembly and
qualitative or quantitative production. Clinical criteria encompass joint hypermobility, skin
hyperextensibility, tissue fragility, and variable internal organ involvement dependent upon
deficits in specific collagen types. Associations with pain, easy bruising, dislocations,
abnormal wound healing, and vascular/visceral manifestations impact quality of life.
As understanding expands through next-generation sequencing, EDS therapies aim to address
comorbidities through targeted exercise, bracing, surgeries empowering mobility and
vocational participation. Palliative strategies focus managing chronic pain syndromes as a
key priority. Differential diagnoses also include overlapping conditions sharing clinical and
genetic heterogeneity complicated classification. This review summarizes EDS subtypes,
molecular etiologies disrupting collagen genes, multisystem manifestations, diagnostic
criteria, and management strategies promoting wellness through precision care frameworks.
Collagen Overview and Biosynthesis
Collagens represent a family of fibrous structural proteins and ECM components essential to
tissue integrity. 28 types assemble into copolymers and higher-order structures conferring
strength and flexibility:
- Fibrillar collagens (I, II, III) form fibrils providing tensile strength in skin, bone, vessels.
- FACIT collagens (IX, XII, XIV) associate fibrils to other ECM components or cells.
- Transmembrane collagens (XVII, XXIII, XXV) mediate cell-matrix adhesion.
- Multiplexed triple helical domains form after intracellular post-translational hydroxylation,
glycosylation, and extracellular processing steps requiring chaperones, modifying enzymes,
and metals.
Qualitative or quantitative collagen defects disrupt tissue development, repair, and
homeostasis underlying heritable connective tissue disorders.
EDS Subtypes and Genetic Etiologies
13 subtypes delineated based on inheritance patterns and defects in specific collagen
genes/processing enzymes:
- Classical EDS (I, II) - Haploinsufficiency of COL5A1/2 collagen genes.
- Hypermobile EDS - Unknown etiology, associations with tenascin-X, COL3A1 variants.
- Vascular EDS (IV) - Heterozygous COL3A1 mutations cause vascular fragility.
- Kyphoscoliotic (VI) - Recessive proα1(I) collagen (COL1A1, COL1A2) defects cause bone
fragility.
- Arthrochalasia (VIIA, VIIB) - Recessive ADAMTS2/17 mutations impair collagen
processing.
Less common subtypes involve collagen XII, XI, XXII genes or chaperone/enzyme
deficiencies impacting specific collagen assembly steps underlying distinct connective tissue
presentations.
Clinical Features of EDS
Manifestations vary between/within subtypes depending on affected collagen, but may
include:
- Joint hypermobility - Loose/stretchy joints, frequent dislocations, instability.
- Skin hyperextensibility - Stretch marks, smooth/velvety skin, visible veins, easy bruising.
- Tissue fragility - Delayed wound healing, hernias, organ ruptures from minor trauma.
- Musculoskeletal - Scoliosis, pectus deformities, joint pain/subluxations/arthritis.
- Vascular fragility - Spontaneous arterial/intestinal perforations, aortic root dilations.
- Other - Mitral valve prolapse, pudgy fingers, colonic inertia, chronic fatigue,
musculoskeletal pain.
Manifestations vary age-dependently and combined clinical/molecular analysis optimizes
diagnosis.
Diagnosis
Diagnosis requires thorough clinical examination and patient/family histories to evaluate
patterns:
- 2017 International EDS Criteria delineate major/minor features to diagnose major subtypes.
- Genetic counseling assesses mode of inheritance and recurrence risks.
- Molecular testing confirms diagnosis if a pathogenic variant is identified in a tested EDS
gene.
- Differential diagnosis excludes conditions mimicking EDS like Marfan/Loeys-Dietz
syndromes.
Diagnosis guides prognosis, screening/management recommendations, and genetic
counseling of relatives regarding inheritance and reproductive risks where applicable.
Management
Treatment follows a multidisciplinary approach focusing overall wellness:
- Physical/occupational therapy addressing muscle weakness/contractures through
customized exercises.
- Bracing/orthotics minimize joint instability. Splinting assists tissue repair.
- Surgical interventions reconstruct joints, hernias, address vascular/dural ectasia.
- Physician-supervised high-protein diet boosts collagen synthesis.
- Contraceptives used for menorrhagia alleviate bleeding in some subtypes.
- Co-management of chronic pain syndromes utilizes medications, injections, devices.
- Counseling addresses issues like fatigue, anxiety, body image concerns.
- Genetic screening determines risk/carrier status of family members enabling early
interventions optimizing function over the lifespan.
Future prospects
Progress promotes wellness through precision frameworks tailoring integrative care
according to collaborative subtype definitions optimizing outcomes. Identifying modifier
genes impacting variable expressivity and developing anti-fibrotic therapeutics addressing
underlying defects holds promise improving quality of life for individuals affected by
heritable collagen-related connective tissue disorders.
Ehlers-Danlos syndrome (EDS) represents a spectrum of heritable connective tissue disorders
arising from defects in collagen synthesis, structure, or processing. Over 13 subtypes have
been delineated based on distinct genetic variants impacting collagen assembly and
qualitative or quantitative production. Clinical criteria encompass joint hypermobility, skin
hyperextensibility, tissue fragility, and variable internal organ involvement dependent upon
deficits in specific collagen types. Associations with pain, easy bruising, dislocations,
abnormal wound healing, and vascular/visceral manifestations impact quality of life.
As understanding expands through next-generation sequencing, EDS therapies aim to address
comorbidities through targeted exercise, bracing, surgeries empowering mobility and
vocational participation. Palliative strategies focus managing chronic pain syndromes as a
key priority. Differential diagnoses also include overlapping conditions sharing clinical and
genetic heterogeneity complicated classification. This review summarizes EDS subtypes,
molecular etiologies disrupting collagen genes, multisystem manifestations, diagnostic
criteria, and management strategies promoting wellness through precision care frameworks.
Collagen Overview and Biosynthesis
Collagens represent a family of fibrous structural proteins and ECM components essential to
tissue integrity. 28 types assemble into copolymers and higher-order structures conferring
strength and flexibility:
- Fibrillar collagens (I, II, III) form fibrils providing tensile strength in skin, bone, vessels.
- FACIT collagens (IX, XII, XIV) associate fibrils to other ECM components or cells.
- Transmembrane collagens (XVII, XXIII, XXV) mediate cell-matrix adhesion.
- Multiplexed triple helical domains form after intracellular post-translational hydroxylation,
glycosylation, and extracellular processing steps requiring chaperones, modifying enzymes,
and metals.
Qualitative or quantitative collagen defects disrupt tissue development, repair, and
homeostasis underlying heritable connective tissue disorders.
EDS Subtypes and Genetic Etiologies
13 subtypes delineated based on inheritance patterns and defects in specific collagen
genes/processing enzymes:
- Classical EDS (I, II) - Haploinsufficiency of COL5A1/2 collagen genes.
- Hypermobile EDS - Unknown etiology, associations with tenascin-X, COL3A1 variants.
- Vascular EDS (IV) - Heterozygous COL3A1 mutations cause vascular fragility.
- Kyphoscoliotic (VI) - Recessive proα1(I) collagen (COL1A1, COL1A2) defects cause bone
fragility.
- Arthrochalasia (VIIA, VIIB) - Recessive ADAMTS2/17 mutations impair collagen
processing.
Less common subtypes involve collagen XII, XI, XXII genes or chaperone/enzyme
deficiencies impacting specific collagen assembly steps underlying distinct connective tissue
presentations.
Clinical Features of EDS
Manifestations vary between/within subtypes depending on affected collagen, but may
include:
- Joint hypermobility - Loose/stretchy joints, frequent dislocations, instability.
- Skin hyperextensibility - Stretch marks, smooth/velvety skin, visible veins, easy bruising.
- Tissue fragility - Delayed wound healing, hernias, organ ruptures from minor trauma.
- Musculoskeletal - Scoliosis, pectus deformities, joint pain/subluxations/arthritis.
- Vascular fragility - Spontaneous arterial/intestinal perforations, aortic root dilations.
- Other - Mitral valve prolapse, pudgy fingers, colonic inertia, chronic fatigue,
musculoskeletal pain.
Manifestations vary age-dependently and combined clinical/molecular analysis optimizes
diagnosis.
Diagnosis
Diagnosis requires thorough clinical examination and patient/family histories to evaluate
patterns:
- 2017 International EDS Criteria delineate major/minor features to diagnose major subtypes.
- Genetic counseling assesses mode of inheritance and recurrence risks.
- Molecular testing confirms diagnosis if a pathogenic variant is identified in a tested EDS
gene.
- Differential diagnosis excludes conditions mimicking EDS like Marfan/Loeys-Dietz
syndromes.
Diagnosis guides prognosis, screening/management recommendations, and genetic
counseling of relatives regarding inheritance and reproductive risks where applicable.
Management
Treatment follows a multidisciplinary approach focusing overall wellness:
- Physical/occupational therapy addressing muscle weakness/contractures through
customized exercises.
- Bracing/orthotics minimize joint instability. Splinting assists tissue repair.
- Surgical interventions reconstruct joints, hernias, address vascular/dural ectasia.
- Physician-supervised high-protein diet boosts collagen synthesis.
- Contraceptives used for menorrhagia alleviate bleeding in some subtypes.
- Co-management of chronic pain syndromes utilizes medications, injections, devices.
- Counseling addresses issues like fatigue, anxiety, body image concerns.
- Genetic screening determines risk/carrier status of family members enabling early
interventions optimizing function over the lifespan.
Future prospects
Progress promotes wellness through precision frameworks tailoring integrative care
according to collaborative subtype definitions optimizing outcomes. Identifying modifier
genes impacting variable expressivity and developing anti-fibrotic therapeutics addressing
underlying defects holds promise improving quality of life for individuals affected by
heritable collagen-related connective tissue disorders.
Ehlers-Danlos syndrome (EDS) represents a spectrum of heritable connective tissue disorders
arising from defects in collagen synthesis, structure, or processing. Over 13 subtypes have
been delineated based on distinct genetic variants impacting collagen assembly and
qualitative or quantitative production. Clinical criteria encompass joint hypermobility, skin
hyperextensibility, tissue fragility, and variable internal organ involvement dependent upon
deficits in specific collagen types. Associations with pain, easy bruising, dislocations,
abnormal wound healing, and vascular/visceral manifestations impact quality of life.
As understanding expands through next-generation sequencing, EDS therapies aim to address
comorbidities through targeted exercise, bracing, surgeries empowering mobility and
vocational participation. Palliative strategies focus managing chronic pain syndromes as a
key priority. Differential diagnoses also include overlapping conditions sharing clinical and
genetic heterogeneity complicated classification. This review summarizes EDS subtypes,
molecular etiologies disrupting collagen genes, multisystem manifestations, diagnostic
criteria, and management strategies promoting wellness through precision care frameworks.
Collagen Overview and Biosynthesis
Collagens represent a family of fibrous structural proteins and ECM components essential to
tissue integrity. 28 types assemble into copolymers and higher-order structures conferring
strength and flexibility:
- Fibrillar collagens (I, II, III) form fibrils providing tensile strength in skin, bone, vessels.
- FACIT collagens (IX, XII, XIV) associate fibrils to other ECM components or cells.
- Transmembrane collagens (XVII, XXIII, XXV) mediate cell-matrix adhesion.
- Multiplexed triple helical domains form after intracellular post-translational hydroxylation,
glycosylation, and extracellular processing steps requiring chaperones, modifying enzymes,
and metals.
Qualitative or quantitative collagen defects disrupt tissue development, repair, and
homeostasis underlying heritable connective tissue disorders.
EDS Subtypes and Genetic Etiologies
13 subtypes delineated based on inheritance patterns and defects in specific collagen
genes/processing enzymes:
- Classical EDS (I, II) - Haploinsufficiency of COL5A1/2 collagen genes.
- Hypermobile EDS - Unknown etiology, associations with tenascin-X, COL3A1 variants.
- Vascular EDS (IV) - Heterozygous COL3A1 mutations cause vascular fragility.
- Kyphoscoliotic (VI) - Recessive proα1(I) collagen (COL1A1, COL1A2) defects cause bone
fragility.
- Arthrochalasia (VIIA, VIIB) - Recessive ADAMTS2/17 mutations impair collagen
processing.
Less common subtypes involve collagen XII, XI, XXII genes or chaperone/enzyme
deficiencies impacting specific collagen assembly steps underlying distinct connective tissue
presentations.
Clinical Features of EDS
Manifestations vary between/within subtypes depending on affected collagen, but may
include:
- Joint hypermobility - Loose/stretchy joints, frequent dislocations, instability.
- Skin hyperextensibility - Stretch marks, smooth/velvety skin, visible veins, easy bruising.
- Tissue fragility - Delayed wound healing, hernias, organ ruptures from minor trauma.
- Musculoskeletal - Scoliosis, pectus deformities, joint pain/subluxations/arthritis.
- Vascular fragility - Spontaneous arterial/intestinal perforations, aortic root dilations.
- Other - Mitral valve prolapse, pudgy fingers, colonic inertia, chronic fatigue,
musculoskeletal pain.
Manifestations vary age-dependently and combined clinical/molecular analysis optimizes
diagnosis.
Diagnosis
Diagnosis requires thorough clinical examination and patient/family histories to evaluate
patterns:
- 2017 International EDS Criteria delineate major/minor features to diagnose major subtypes.
- Genetic counseling assesses mode of inheritance and recurrence risks.
- Molecular testing confirms diagnosis if a pathogenic variant is identified in a tested EDS
gene.
- Differential diagnosis excludes conditions mimicking EDS like Marfan/Loeys-Dietz
syndromes.
Diagnosis guides prognosis, screening/management recommendations, and genetic
counseling of relatives regarding inheritance and reproductive risks where applicable.
Management
Treatment follows a multidisciplinary approach focusing overall wellness:
- Physical/occupational therapy addressing muscle weakness/contractures through
customized exercises.
- Bracing/orthotics minimize joint instability. Splinting assists tissue repair.
- Surgical interventions reconstruct joints, hernias, address vascular/dural ectasia.
- Physician-supervised high-protein diet boosts collagen synthesis.
- Contraceptives used for menorrhagia alleviate bleeding in some subtypes.
- Co-management of chronic pain syndromes utilizes medications, injections, devices.
- Counseling addresses issues like fatigue, anxiety, body image concerns.
- Genetic screening determines risk/carrier status of family members enabling early
interventions optimizing function over the lifespan.
Future prospects
Progress promotes wellness through precision frameworks tailoring integrative care
according to collaborative subtype definitions optimizing outcomes. Identifying modifier
genes impacting variable expressivity and developing anti-fibrotic therapeutics addressing
underlying defects holds promise improving quality of life for individuals affected by
heritable collagen-related connective tissue disorders.
Ehlers-Danlos syndrome (EDS) represents a spectrum of heritable connective tissue disorders
arising from defects in collagen synthesis, structure, or processing. Over 13 subtypes have
been delineated based on distinct genetic variants impacting collagen assembly and
qualitative or quantitative production. Clinical criteria encompass joint hypermobility, skin
hyperextensibility, tissue fragility, and variable internal organ involvement dependent upon
deficits in specific collagen types. Associations with pain, easy bruising, dislocations,
abnormal wound healing, and vascular/visceral manifestations impact quality of life.
As understanding expands through next-generation sequencing, EDS therapies aim to address
comorbidities through targeted exercise, bracing, surgeries empowering mobility and
vocational participation. Palliative strategies focus managing chronic pain syndromes as a
key priority. Differential diagnoses also include overlapping conditions sharing clinical and
genetic heterogeneity complicated classification. This review summarizes EDS subtypes,
molecular etiologies disrupting collagen genes, multisystem manifestations, diagnostic
criteria, and management strategies promoting wellness through precision care frameworks.
Collagen Overview and Biosynthesis
Collagens represent a family of fibrous structural proteins and ECM components essential to
tissue integrity. 28 types assemble into copolymers and higher-order structures conferring
strength and flexibility:
- Fibrillar collagens (I, II, III) form fibrils providing tensile strength in skin, bone, vessels.
- FACIT collagens (IX, XII, XIV) associate fibrils to other ECM components or cells.
- Transmembrane collagens (XVII, XXIII, XXV) mediate cell-matrix adhesion.
- Multiplexed triple helical domains form after intracellular post-translational hydroxylation,
glycosylation, and extracellular processing steps requiring chaperones, modifying enzymes,
and metals.
Qualitative or quantitative collagen defects disrupt tissue development, repair, and
homeostasis underlying heritable connective tissue disorders.
EDS Subtypes and Genetic Etiologies
13 subtypes delineated based on inheritance patterns and defects in specific collagen
genes/processing enzymes:
- Classical EDS (I, II) - Haploinsufficiency of COL5A1/2 collagen genes.
- Hypermobile EDS - Unknown etiology, associations with tenascin-X, COL3A1 variants.
- Vascular EDS (IV) - Heterozygous COL3A1 mutations cause vascular fragility.
- Kyphoscoliotic (VI) - Recessive proα1(I) collagen (COL1A1, COL1A2) defects cause bone
fragility.
- Arthrochalasia (VIIA, VIIB) - Recessive ADAMTS2/17 mutations impair collagen
processing.
Less common subtypes involve collagen XII, XI, XXII genes or chaperone/enzyme
deficiencies impacting specific collagen assembly steps underlying distinct connective tissue
presentations.
Clinical Features of EDS
Manifestations vary between/within subtypes depending on affected collagen, but may
include:
- Joint hypermobility - Loose/stretchy joints, frequent dislocations, instability.
- Skin hyperextensibility - Stretch marks, smooth/velvety skin, visible veins, easy bruising.
- Tissue fragility - Delayed wound healing, hernias, organ ruptures from minor trauma.
- Musculoskeletal - Scoliosis, pectus deformities, joint pain/subluxations/arthritis.
- Vascular fragility - Spontaneous arterial/intestinal perforations, aortic root dilations.
- Other - Mitral valve prolapse, pudgy fingers, colonic inertia, chronic fatigue,
musculoskeletal pain.
Manifestations vary age-dependently and combined clinical/molecular analysis optimizes
diagnosis.
Diagnosis
Diagnosis requires thorough clinical examination and patient/family histories to evaluate
patterns:
- 2017 International EDS Criteria delineate major/minor features to diagnose major subtypes.
- Genetic counseling assesses mode of inheritance and recurrence risks.
- Molecular testing confirms diagnosis if a pathogenic variant is identified in a tested EDS
gene.
- Differential diagnosis excludes conditions mimicking EDS like Marfan/Loeys-Dietz
syndromes.
Diagnosis guides prognosis, screening/management recommendations, and genetic
counseling of relatives regarding inheritance and reproductive risks where applicable.
Management
Treatment follows a multidisciplinary approach focusing overall wellness:
- Physical/occupational therapy addressing muscle weakness/contractures through
customized exercises.
- Bracing/orthotics minimize joint instability. Splinting assists tissue repair.
- Surgical interventions reconstruct joints, hernias, address vascular/dural ectasia.
- Physician-supervised high-protein diet boosts collagen synthesis.
- Contraceptives used for menorrhagia alleviate bleeding in some subtypes.
- Co-management of chronic pain syndromes utilizes medications, injections, devices.
- Counseling addresses issues like fatigue, anxiety, body image concerns.
- Genetic screening determines risk/carrier status of family members enabling early
interventions optimizing function over the lifespan.
Future prospects
Progress promotes wellness through precision frameworks tailoring integrative care
according to collaborative subtype definitions optimizing outcomes. Identifying modifier
genes impacting variable expressivity and developing anti-fibrotic therapeutics addressing
underlying defects holds promise improving quality of life for individuals affected by
heritable collagen-related connective tissue disorders.
Ehlers-Danlos syndrome (EDS) represents a spectrum of heritable connective tissue disorders
arising from defects in collagen synthesis, structure, or processing. Over 13 subtypes have
been delineated based on distinct genetic variants impacting collagen assembly and
qualitative or quantitative production. Clinical criteria encompass joint hypermobility, skin
hyperextensibility, tissue fragility, and variable internal organ involvement dependent upon
deficits in specific collagen types. Associations with pain, easy bruising, dislocations,
abnormal wound healing, and vascular/visceral manifestations impact quality of life.
As understanding expands through next-generation sequencing, EDS therapies aim to address
comorbidities through targeted exercise, bracing, surgeries empowering mobility and
vocational participation. Palliative strategies focus managing chronic pain syndromes as a
key priority. Differential diagnoses also include overlapping conditions sharing clinical and
genetic heterogeneity complicated classification. This review summarizes EDS subtypes,
molecular etiologies disrupting collagen genes, multisystem manifestations, diagnostic
criteria, and management strategies promoting wellness through precision care frameworks.
Collagen Overview and Biosynthesis
Collagens represent a family of fibrous structural proteins and ECM components essential to
tissue integrity. 28 types assemble into copolymers and higher-order structures conferring
strength and flexibility:
- Fibrillar collagens (I, II, III) form fibrils providing tensile strength in skin, bone, vessels.
- FACIT collagens (IX, XII, XIV) associate fibrils to other ECM components or cells.
- Transmembrane collagens (XVII, XXIII, XXV) mediate cell-matrix adhesion.
- Multiplexed triple helical domains form after intracellular post-translational hydroxylation,
glycosylation, and extracellular processing steps requiring chaperones, modifying enzymes,
and metals.
Qualitative or quantitative collagen defects disrupt tissue development, repair, and
homeostasis underlying heritable connective tissue disorders.
EDS Subtypes and Genetic Etiologies
13 subtypes delineated based on inheritance patterns and defects in specific collagen
genes/processing enzymes:
- Classical EDS (I, II) - Haploinsufficiency of COL5A1/2 collagen genes.
- Hypermobile EDS - Unknown etiology, associations with tenascin-X, COL3A1 variants.
- Vascular EDS (IV) - Heterozygous COL3A1 mutations cause vascular fragility.
- Kyphoscoliotic (VI) - Recessive proα1(I) collagen (COL1A1, COL1A2) defects cause bone
fragility.
- Arthrochalasia (VIIA, VIIB) - Recessive ADAMTS2/17 mutations impair collagen
processing.
Less common subtypes involve collagen XII, XI, XXII genes or chaperone/enzyme
deficiencies impacting specific collagen assembly steps underlying distinct connective tissue
presentations.
Clinical Features of EDS
Manifestations vary between/within subtypes depending on affected collagen, but may
include:
- Joint hypermobility - Loose/stretchy joints, frequent dislocations, instability.
- Skin hyperextensibility - Stretch marks, smooth/velvety skin, visible veins, easy bruising.
- Tissue fragility - Delayed wound healing, hernias, organ ruptures from minor trauma.
- Musculoskeletal - Scoliosis, pectus deformities, joint pain/subluxations/arthritis.
- Vascular fragility - Spontaneous arterial/intestinal perforations, aortic root dilations.
- Other - Mitral valve prolapse, pudgy fingers, colonic inertia, chronic fatigue,
musculoskeletal pain.
Manifestations vary age-dependently and combined clinical/molecular analysis optimizes
diagnosis.
Diagnosis
Diagnosis requires thorough clinical examination and patient/family histories to evaluate
patterns:
- 2017 International EDS Criteria delineate major/minor features to diagnose major subtypes.
- Genetic counseling assesses mode of inheritance and recurrence risks.
- Molecular testing confirms diagnosis if a pathogenic variant is identified in a tested EDS
gene.
- Differential diagnosis excludes conditions mimicking EDS like Marfan/Loeys-Dietz
syndromes.
Diagnosis guides prognosis, screening/management recommendations, and genetic
counseling of relatives regarding inheritance and reproductive risks where applicable.
Management
Treatment follows a multidisciplinary approach focusing overall wellness:
- Physical/occupational therapy addressing muscle weakness/contractures through
customized exercises.
- Bracing/orthotics minimize joint instability. Splinting assists tissue repair.
- Surgical interventions reconstruct joints, hernias, address vascular/dural ectasia.
- Physician-supervised high-protein diet boosts collagen synthesis.
- Contraceptives used for menorrhagia alleviate bleeding in some subtypes.
- Co-management of chronic pain syndromes utilizes medications, injections, devices.
- Counseling addresses issues like fatigue, anxiety, body image concerns.
- Genetic screening determines risk/carrier status of family members enabling early
interventions optimizing function over the lifespan.
Future prospects
Progress promotes wellness through precision frameworks tailoring integrative care
according to collaborative subtype definitions optimizing outcomes. Identifying modifier
genes impacting variable expressivity and developing anti-fibrotic therapeutics addressing
underlying defects holds promise improving quality of life for individuals affected by
heritable collagen-related connective tissue disorders.
Ehlers-Danlos syndrome (EDS) represents a spectrum of heritable connective tissue disorders
arising from defects in collagen synthesis, structure, or processing. Over 13 subtypes have
been delineated based on distinct genetic variants impacting collagen assembly and
qualitative or quantitative production. Clinical criteria encompass joint hypermobility, skin
hyperextensibility, tissue fragility, and variable internal organ involvement dependent upon
deficits in specific collagen types. Associations with pain, easy bruising, dislocations,
abnormal wound healing, and vascular/visceral manifestations impact quality of life.
As understanding expands through next-generation sequencing, EDS therapies aim to address
comorbidities through targeted exercise, bracing, surgeries empowering mobility and
vocational participation. Palliative strategies focus managing chronic pain syndromes as a
key priority. Differential diagnoses also include overlapping conditions sharing clinical and
genetic heterogeneity complicated classification. This review summarizes EDS subtypes,
molecular etiologies disrupting collagen genes, multisystem manifestations, diagnostic
criteria, and management strategies promoting wellness through precision care frameworks.
Collagen Overview and Biosynthesis
Collagens represent a family of fibrous structural proteins and ECM components essential to
tissue integrity. 28 types assemble into copolymers and higher-order structures conferring
strength and flexibility:
- Fibrillar collagens (I, II, III) form fibrils providing tensile strength in skin, bone, vessels.
- FACIT collagens (IX, XII, XIV) associate fibrils to other ECM components or cells.
- Transmembrane collagens (XVII, XXIII, XXV) mediate cell-matrix adhesion.
- Multiplexed triple helical domains form after intracellular post-translational hydroxylation,
glycosylation, and extracellular processing steps requiring chaperones, modifying enzymes,
and metals.
Qualitative or quantitative collagen defects disrupt tissue development, repair, and
homeostasis underlying heritable connective tissue disorders.
EDS Subtypes and Genetic Etiologies
13 subtypes delineated based on inheritance patterns and defects in specific collagen
genes/processing enzymes:
- Classical EDS (I, II) - Haploinsufficiency of COL5A1/2 collagen genes.
- Hypermobile EDS - Unknown etiology, associations with tenascin-X, COL3A1 variants.
- Vascular EDS (IV) - Heterozygous COL3A1 mutations cause vascular fragility.
- Kyphoscoliotic (VI) - Recessive proα1(I) collagen (COL1A1, COL1A2) defects cause bone
fragility.
- Arthrochalasia (VIIA, VIIB) - Recessive ADAMTS2/17 mutations impair collagen
processing.
Less common subtypes involve collagen XII, XI, XXII genes or chaperone/enzyme
deficiencies impacting specific collagen assembly steps underlying distinct connective tissue
presentations.
Clinical Features of EDS
Manifestations vary between/within subtypes depending on affected collagen, but may
include:
- Joint hypermobility - Loose/stretchy joints, frequent dislocations, instability.
- Skin hyperextensibility - Stretch marks, smooth/velvety skin, visible veins, easy bruising.
- Tissue fragility - Delayed wound healing, hernias, organ ruptures from minor trauma.
- Musculoskeletal - Scoliosis, pectus deformities, joint pain/subluxations/arthritis.
- Vascular fragility - Spontaneous arterial/intestinal perforations, aortic root dilations.
- Other - Mitral valve prolapse, pudgy fingers, colonic inertia, chronic fatigue,
musculoskeletal pain.
Manifestations vary age-dependently and combined clinical/molecular analysis optimizes
diagnosis.
Diagnosis
Diagnosis requires thorough clinical examination and patient/family histories to evaluate
patterns:
- 2017 International EDS Criteria delineate major/minor features to diagnose major subtypes.
- Genetic counseling assesses mode of inheritance and recurrence risks.
- Molecular testing confirms diagnosis if a pathogenic variant is identified in a tested EDS
gene.
- Differential diagnosis excludes conditions mimicking EDS like Marfan/Loeys-Dietz
syndromes.
Diagnosis guides prognosis, screening/management recommendations, and genetic
counseling of relatives regarding inheritance and reproductive risks where applicable.
Management
Treatment follows a multidisciplinary approach focusing overall wellness:
- Physical/occupational therapy addressing muscle weakness/contractures through
customized exercises.
- Bracing/orthotics minimize joint instability. Splinting assists tissue repair.
- Surgical interventions reconstruct joints, hernias, address vascular/dural ectasia.
- Physician-supervised high-protein diet boosts collagen synthesis.
- Contraceptives used for menorrhagia alleviate bleeding in some subtypes.
- Co-management of chronic pain syndromes utilizes medications, injections, devices.
- Counseling addresses issues like fatigue, anxiety, body image concerns.
- Genetic screening determines risk/carrier status of family members enabling early
interventions optimizing function over the lifespan.
Future prospects
Progress promotes wellness through precision frameworks tailoring integrative care
according to collaborative subtype definitions optimizing outcomes. Identifying modifier
genes impacting variable expressivity and developing anti-fibrotic therapeutics addressing
underlying defects holds promise improving quality of life for individuals affected by
heritable collagen-related connective tissue disorders.
